Literature DB >> 22722798

Rare and novel epidermal growth factor receptor mutations in non-small-cell lung cancer and lack of clinical response to gefitinib in two cases.

Amit Sharma, Thean H Tan, Glenice Cheetham, Hamish S Scott, Michael P Brown.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22722798     DOI： 10.1097/JTO.0b013e31825134ac

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  4 in total

1.  Distinct EGFR Mutation Pattern in Patients With Non-Small Cell Lung Cancer in Xuanwei Region of China: A Systematic Review and Meta-Analysis.

Authors:  Li Lv; Zhichao Liu; Yang Liu; Wenhui Zhang; Lifeng Jiang; Tingting Li; Xinyan Lu; Xuefen Lei; Wenhua Liang; Jie Lin
Journal:  Front Oncol       Date:  2020-11-02       Impact factor: 6.244

2.  Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q.

Authors:  Satoshi Watanabe; Yuji Minegishi; Hirohisa Yoshizawa; Makoto Maemondo; Akira Inoue; Shunichi Sugawara; Hiroshi Isobe; Masao Harada; Yoshiki Ishii; Akihiko Gemma; Koichi Hagiwara; Kunihiko Kobayashi
Journal:  J Thorac Oncol       Date:  2014-02       Impact factor: 15.609

Review 3.  The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review).

Authors:  Fatima Ardito; Michele Giuliani; Donatella Perrone; Giuseppe Troiano; Lorenzo Lo Muzio
Journal:  Int J Mol Med       Date:  2017-06-22       Impact factor: 4.101

4.  Detection and characterization of classical and "uncommon" exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing.

Authors:  Luisella Righi; Alessandra Cuccurullo; Simona Vatrano; Susanna Cappia; Daniela Giachino; Paolo De Giuli; Mara Ardine; Silvia Novello; Marco Volante; Giorgio V Scagliotti; Mauro Papotti
Journal:  BMC Cancer       Date:  2013-03-13       Impact factor: 4.430
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.